{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:46:34Z","timestamp":1791913594882,"version":"4.3.4"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T00:00:00Z","timestamp":1636934400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.lungcan.2021.11.001","type":"journal-article","created":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T20:57:34Z","timestamp":1636491454000},"page":"185-193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013\u20132017: A nationwide CAS registry analysis from the I-O Optimise initiative"],"prefix":"10.1016","volume":"162","author":[{"given":"Paul","family":"Baas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda J.","family":"Daumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Lacoin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Penrod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhir","family":"Venkatesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harveen","family":"Ubhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Calleja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Snee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2021.11.001_b0005","unstructured":"International Agency for Research on Cancer, GLOBOCAN 2020: Mesothelioma 2020. https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/18-Mesothelioma-fact-sheet.pdf. (Accessed March 2021)."},{"issue":"Suppl 5","key":"10.1016\/j.lungcan.2021.11.001_b0010","doi-asserted-by":"crossref","first-page":"v31","DOI":"10.1093\/annonc\/mdv199","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Baas","year":"2015","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2021.11.001_b0015","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/thx.52.6.507","article-title":"Malignant mesothelioma in south east England: clinicopathological experience of 272 cases","volume":"52","author":"Yates","year":"1997","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.lungcan.2021.11.001_b0020","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/oem.54.6.403","article-title":"Routes of asbestos exposure and the development of mesothelioma in an English region","volume":"54","author":"Howel","year":"1997","journal-title":"Occup. Environ. Med."},{"issue":"9","key":"10.1016\/j.lungcan.2021.11.001_b0025","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/thorax.55.9.731","article-title":"Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems","volume":"55","author":"Edwards","year":"2000","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.lungcan.2021.11.001_b0030","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1136\/thx.2007.081430","article-title":"Population based epidemiology and prognosis of mesothelioma in Leeds, UK","volume":"63","author":"Chapman","year":"2008","journal-title":"Thorax"},{"issue":"Suppl 1","key":"10.1016\/j.lungcan.2021.11.001_b0035","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thoraxjnl-2017-211321","article-title":"British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma","volume":"73","author":"Woolhouse","year":"2018","journal-title":"Thorax"},{"issue":"Suppl 1","key":"10.1016\/j.lungcan.2021.11.001_b0040","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.21037\/tlcr.2019.11.11","article-title":"Epidemiology of mesothelioma in the 21(st) century in Europe and the United States, 40 years after restricted\/banned asbestos use","volume":"9","author":"Alpert","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2021.11.001_b0045","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/jcp.22724","article-title":"Malignant mesothelioma: facts, myths, and hypotheses","volume":"227","author":"Carbone","year":"2012","journal-title":"J. Cell. Physiol."},{"issue":"1","key":"10.1016\/j.lungcan.2021.11.001_b0050","first-page":"70","article-title":"Mesothelioma: a review","volume":"12","author":"Mott","year":"2012","journal-title":"Ochsner. J."},{"issue":"142","key":"10.1016\/j.lungcan.2021.11.001_b0055","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1183\/16000617.0063-2016","article-title":"Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment","volume":"25","author":"Bibby","year":"2016","journal-title":"Eur. Respir. Rev."},{"issue":"6","key":"10.1016\/j.lungcan.2021.11.001_b0060","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.2307\/3580117","article-title":"The German Thorotrast study: recent results and assessment of risks","volume":"152","author":"van Kaick","year":"1999","journal-title":"Radiat. Res."},{"issue":"Suppl. 2","key":"10.1016\/j.lungcan.2021.11.001_b0065","doi-asserted-by":"crossref","first-page":"S276","DOI":"10.21037\/jtd.2017.10.125","article-title":"The pathological and molecular diagnosis of malignant pleural mesothelioma: a literature review","volume":"10","author":"Ali","year":"2018","journal-title":"J. Thorac. Dis."},{"issue":"4","key":"10.1016\/j.lungcan.2021.11.001_b0070","first-page":"438","article-title":"Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database","volume":"1","author":"Rusch","year":"2012","journal-title":"Ann. Cardiothorac. Surg."},{"issue":"12","key":"10.1016\/j.lungcan.2021.11.001_b0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145039","article-title":"Determinants of survival in malignant pleural mesothelioma: a surveillance, epidemiology, and end results (SEER) study of 14,228 patients","volume":"10","author":"Taioli","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.lungcan.2021.11.001_b0080","unstructured":"Royal College of Physicians, National Mesothelioma Audit Report 2020 (Audit Period 2016-18), 2020. https:\/\/www.rcplondon.ac.uk\/projects\/outputs\/national-mesothelioma-audit-report-2020-audit-period-2016-18. (Accessed March 2021)."},{"issue":"14","key":"10.1016\/j.lungcan.2021.11.001_b0085","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2021.11.001_b0090","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12890-021-01513-7","article-title":"Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma","volume":"21","author":"Gray","year":"2021","journal-title":"BMC Pulm. Med."},{"issue":"15","key":"10.1016\/j.lungcan.2021.11.001_b0095","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMra050152","article-title":"Advances in malignant mesothelioma","volume":"353","author":"Robinson","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.lungcan.2021.11.001_b0100","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.2217\/fon-2019-0025","article-title":"a novel multinational real-world research platform in thoracic malignancies","volume":"15","author":"Ekman","year":"2019","journal-title":"Future Oncol."},{"key":"10.1016\/j.lungcan.2021.11.001_b0105","unstructured":"The National Cancer Registration and Analysis Service (NCRAS), CAS Explorer, 2021. https:\/\/www.cancerdata.nhs.uk\/explorer. (Accessed March 2021)."},{"issue":"3","key":"10.1016\/j.lungcan.2021.11.001_b0110","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.lungcan.2015.03.005","article-title":"Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales","volume":"88","author":"Beckett","year":"2015","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2021.11.001_b0115","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.lungcan.2015.05.014","article-title":"Treatment patterns and survival analysis in 9014 patients with malignant pleural mesothelioma from Belgium, the Netherlands and England","volume":"89","author":"Damhuis","year":"2015","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2021.11.001_b0120","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/0284186X.2018.1532599","article-title":"Malignant pleural mesothelioma in Finland: regional and gender variation","volume":"58","author":"Laaksonen","year":"2019","journal-title":"Acta Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2021.11.001_b0125","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.athoracsur.2017.09.036","article-title":"National trends in the epidemiology of malignant pleural mesothelioma: a National Cancer Data Base study","volume":"105","author":"Saddoughi","year":"2018","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.lungcan.2021.11.001_b0130","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1186\/s12885-015-1881-x","article-title":"Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)","volume":"15","author":"Raynaud","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lungcan.2021.11.001_b0135","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.lungcan.2018.10.009","article-title":"Real-life treatment practice for malignant pleural mesothelioma in Belgium","volume":"125","author":"Rosskamp","year":"2018","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2021.11.001_b0140","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.1998.16.1.145","article-title":"Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience","volume":"16","author":"Curran","year":"1998","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2021.11.001_b0145","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1378\/chest.113.3.723","article-title":"Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B","volume":"113","author":"Herndon","year":"1998","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.lungcan.2021.11.001_b0150","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1097\/JTO.0b013e3181f1cf2b","article-title":"Malignant pleural mesothelioma: a population-based study of survival","volume":"5","author":"Milano","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2021.11.001_b0155","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.lungcan.2020.06.034","article-title":"Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group","volume":"147","author":"Remon","year":"2020","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2021.11.001_b0160","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1200\/JCO.2005.07.050","article-title":"Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive Phase II trials","volume":"23","author":"Fennell","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2021.11.001_b0165","unstructured":"Health and Social Care Information Centre, National Lung Cancer Audit Report 2014 mesothelioma: Report for the period 2008-2012, 2014. https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/national-lung-cancer-audit\/national-lung-cancer-audit-report-2014-mesothelioma."},{"key":"10.1016\/j.lungcan.2021.11.001_b0170","doi-asserted-by":"crossref","unstructured":"A. Trama, C. Proto, D. Signorelli, M.C. Garassino, G. Lo Russo, M. Ganzinelli, A. Prelaj, C. Mensi, M. Gangemi, V. Gennaro, E. Chellini, A. Caldarella, I.F. Angelillo, V. Ascoli, C. Pascucci, G. Tagliabue, R. Cusimano, F. Bella, F. Falcini, E. Merler, G. Masanotti, A. Ziino, M. Michiara, G. Gola, C. Storchi, L. Mangone, M.F. Vitale, C. Cirilli, R. Tumino, T. Scuderi, A.C. Fanetti, S. Piffer, M. Tiseo, G. Gatta, L. Botta, LUME study WG, Treatment patterns among patients with malignant pleural mesothelioma: An Italian, population-based nationwide study, Thorac. Cancer 11 (6) (2020) 1661-1669. https:\/\/doi.org\/10.1111\/1759-7714.13456.","DOI":"10.1111\/1759-7714.13456"},{"key":"10.1016\/j.lungcan.2021.11.001_b0175","doi-asserted-by":"crossref","unstructured":"A. Scherpereel, P. Astoul, P. Baas, T. Berghmans, H. Clayson, P. de Vuyst, H. Dienemann, F. Galateau-Salle, C. Hennequin, G. Hillerdal, C. Le Pechoux, L. Mutti, J.C. Pairon, R. Stahel, P. van Houtte, J. van Meerbeeck, D. Waller, W. Weder, European Respiratory Society\/European Society of Thoracic Surgeons Task Force, Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma, Eur. Respir. J. 35 (3) (2010) 479-95. https:\/\/doi.org\/10.1183\/09031936.00063109.","DOI":"10.1183\/09031936.00063109"},{"issue":"10272","key":"10.1016\/j.lungcan.2021.11.001_b0180","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2021.11.001_b0185","doi-asserted-by":"crossref","first-page":"S1283","DOI":"10.1016\/j.annonc.2021.08.2146","article-title":"First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743","volume":"32","author":"Peters","year":"2021","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2021.11.001_b0190","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","article-title":"Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma","volume":"13","author":"Quispel-Janssen","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"18","key":"10.1016\/j.lungcan.2021.11.001_b0195","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","article-title":"Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese Phase II study in malignant pleural mesothelioma (MERIT)","volume":"25","author":"Okada","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2021.11.001_b9000","unstructured":"U.S. Food & Drug Administration. FDA approves nivolumab and ipilimumab for unresectable malignant pleural mesothelioma, 2020. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-nivolumab-and-ipilimumab-unresectable-malignant-pleural-mesothelioma. (Accessed September 2021)."},{"key":"10.1016\/j.lungcan.2021.11.001_b0200","unstructured":"Bristol Myers Squibb, Bristol Myers Squibb receives European Commission approval for OPDIVO (nivolumab) plus YERVOY (ipilimumab) as first-line treatment for unresectable malignant pleural mesothelioma, 2021. https:\/\/news.bms.com\/news\/details\/2021\/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-as-First-Line-Treatment-for-Unresectable-Malignant-Pleural-Mesothelioma\/default.aspx. (Accessed September 2021)."},{"key":"10.1016\/j.lungcan.2021.11.001_b0205","unstructured":"NICE, NHS England interim treatment options during the COVID-19 pandemic, 2021. https:\/\/www.nice.org.uk\/guidance\/ng161\/resources\/interim-treatment-change-options-during-the-covid19-pandemic-endorsed-by-nhs-england-pdf-8715724381. (Accessed Spetember 2021)."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022100595X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022100595X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:57:30Z","timestamp":1791910650000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016950022100595X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":42,"alternative-id":["S016950022100595X"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2021.11.001","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013\u20132017: A nationwide CAS registry analysis from the I-O Optimise initiative","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2021.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}